- BNF:
- 8.2.4
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- February 2017
Comments
RED:1,2,3 NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib.
DO NOT PRESCRIBE (DNP)6: NICE TA602: Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma. (Terminated appraisal, decision date - Oct 2019)
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again